Ra Capital Management as of Dec. 31, 2017
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 27 positions in its portfolio as reported in the December 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Wave Life Sciences (WVE) | 22.1 | $264M | 7.5M | 35.10 | |
| Ascendis Pharma A S (ASND) | 18.7 | $224M | 5.6M | 40.06 | |
| Avexis | 10.8 | $130M | 1.2M | 110.67 | |
| Sage Therapeutics (SAGE) | 6.3 | $75M | 455k | 164.71 | |
| Inflarx Nv (IFRX) | 5.0 | $60M | 2.9M | 20.95 | |
| Biohaven Pharmaceutical Holding | 4.5 | $54M | 2.0M | 26.98 | |
| Zogenix | 3.8 | $46M | 1.1M | 40.05 | |
| Dicerna Pharmaceuticals | 3.8 | $45M | 5.0M | 9.03 | |
| Kala Pharmaceuticals | 3.3 | $39M | 2.1M | 18.49 | |
| Myovant Sciences | 3.0 | $36M | 2.8M | 12.64 | |
| Scpharmaceuticals (SCPH) | 2.9 | $35M | 2.9M | 12.09 | |
| BioCryst Pharmaceuticals (BCRX) | 2.9 | $34M | 7.0M | 4.91 | |
| Kadmon Hldgs | 1.9 | $23M | 6.3M | 3.62 | |
| Apellis Pharmaceuticals (APLS) | 1.6 | $20M | 900k | 21.70 | |
| Endocyte | 1.2 | $14M | 3.4M | 4.28 | |
| Spero Therapeutics (SPRO) | 1.2 | $14M | 1.2M | 11.75 | |
| AVEO Pharmaceuticals | 1.2 | $14M | 5.1M | 2.79 | |
| Kalvista Pharmaceuticals (KALV) | 1.2 | $14M | 1.4M | 9.75 | |
| Sunesis Pharmaceuticals Inc Ne | 1.0 | $11M | 3.1M | 3.69 | |
| Ra Pharmaceuticals | 1.0 | $12M | 1.4M | 8.50 | |
| Clementia | 0.9 | $11M | 585k | 18.98 | |
| Krystal Biotech (KRYS) | 0.6 | $7.4M | 700k | 10.52 | |
| Argenx Se (ARGX) | 0.4 | $4.8M | 76k | 63.14 | |
| G1 Therapeutics | 0.3 | $3.2M | 160k | 19.84 | |
| Proteon Therapeutics | 0.2 | $2.5M | 1.3M | 1.90 | |
| Chiasma | 0.2 | $2.0M | 1.2M | 1.70 | |
| Achillion Pharmaceuticals | 0.1 | $1.7M | 586k | 2.88 |
